News

BioNTech SE  and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and…
Read More...

QIAGEN announced a collaboration with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes. The three-year partnership will…
Read More...

Apollo Therapeutics Group Limited (“Apollo”), the portfolio biopharmaceutical company, and Sunshine Lake Pharma Co., Ltd. (“Sunshine Lake”), an innovative pharmaceutical company and a…
Read More...

Ontada®, a McKesson business and leader in community oncology real-world data, clinical education, and point of care technologies, has announced a strategic collaboration with Datavant,…
Read More...

GSK announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk…
Read More...

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on…
Read More...

Aditum Bio and Leads Biolabs announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license agreement to develop LBL-051, a…
Read More...

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced that the…
Read More...

On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D…
Read More...

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers…
Read More...

Nektar Therapeutics, a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered…
Read More...

GSK’s AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada for the prevention of lower respiratory tract disease (LRTD) caused by…
Read More...

Nxera Pharma – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have announced a multi-target partnership…
Read More...

Inocras Inc. and Summit Pharmaceuticals International Corporation signed an MOU (Memorandum of understanding) to jointly explore the commercialization of their whole genome sequencing…
Read More...

Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo…
Read More...

GSK plc and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T…
Read More...

Novartis announced that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed Philadelphia…
Read More...

Biogen Inc. and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and…
Read More...

Iterum Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new drug application for ORLYNVAH (sulopenem etzadroxil and probenecid) for the…
Read More...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with…
Read More...